The Effect Of Dose Titration And Dose Tapering On The Tolerability Of DVS SR In Women With Vasomotor Symptoms

Sponsor

Wyeth Research

Principal Investigator

Dr. John Thorp, Obstetrics and Gynecology

Project Run Dates

1/30/2007 to 1/28/2010

Total Award Amount

$47,472.40

 

Summary

Desvenlafaxine succinate (DVS SR) is a serotonin and norepinephrine reuptake inhibitor (SNRI). It is a nonhormonal option for the treatment of Vasomotor Symptoms (VMS) associated with menopause. Nausea is the most common adverse event that is observed in clinical studies and is the main reason for discontinuation during the first week of therapy. Other adverse events (headache, nausea, and dizziness) associated with DVS SR have been noted to occur when subjects abruptly discontinue the medication. The purpose of this study is to evaluate several titration and tapering regimens of DVS SR to ensure a better tolerability profile at the start and completion of treatment. In addition, this study will provide a long posttreatment follow-up to assess any symptoms after treatment is discontinued.

 

Associated Publications and other materials

 Study Record Detail on Clinical Trials.gov

 

Associated Award Numbers: A07-0978-002, A07-0978-003, A07-0978-004, A07-0978-005, A07-0978-006